6Cheng JD, Babb JS, Langer C, et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936[J]. J Clin Oncol, 2004, 22(4): 602-609.
7Muraille E, De Smedt T, Thielemans K, et al. Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation [J]. Cell Immunol, 1995, 162(2) : 315 -320.
8Kim SH, Chung HK, Kang JH, et al. Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter [J]. Hum Gene Ther, 2008, 19(9) : 951 -957.
9Pericuesta E, Ramfrez MA, Villa-Diaz A, et al. The proximal promot- er region of mTert is sufficient to regulate telomerase activity in ES cells and transgenic animals [ J]. Reprod Biol Endocfinol, 2006, 4(1): 5-10.
10Gu DH, Wang XY, Tang F, et al. Expression and significance of human telomerase reverse transcriptase mRNA in laryngeal squamous cell cancer and its relationship with c-myc [ J ]. FuDan Univ J Med Sci, 2006, 33(4): 459-462.
